Riskpilot← Back to searchSign inGet full accessNORMEDISIN AS
ASActiveOrg 984041322Markangeaidnu 12, 9731 KarasjokMedical specialists activities · NACE 8622Est. 20021 employees
Revenue 2024
NOK 1,5M
-2% vs 2023
EBITDA margin
-11.0%
-117% vs 2023
Equity ratio
93.9%
Financial strength
Net profit 2024
NOK -289K
-139% vs 2023
| Revenue | NOK 1,5M | -2% |
| EBITDA | NOK -162K | -117% |
| Net profit | NOK -289K | -139% |
| Total assets | NOK 2,7M | -29% |
| Equity | NOK 2,5M | -28% |
| Employees | 1 | — |
Legal name
NORMEDISIN AS
Org number
984041322
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
17. januar 2002
Share capital
NOK 100 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Salg av helsetjenester, medisinsk forskning, utvikling av medisinsk utstyr og kjøp og salg av aksjer eller på annen måte gjøre seg interessert i andre foretak.
Address
Markangeaidnu 12, 9731 Karasjok
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 496 | 2 071 | 1 706 | 1 501 | 1 470 |
| Staff expenses | −31 | −0 | −294 | −278 | −466 |
| EBITDA | 1 035 | 1 594 | 871 | 955 | −162 |
| Depreciation & amort. | −4 | −10 | −19 | −0 | −68 |
| EBIT | 1 031 | 1 583 | 852 | 955 | −230 |
| Net financials | −1 | −0 | −202 | −6 | −0 |
| Profit before tax | 1 030 | 1 583 | 650 | 948 | −230 |
| Tax | 111 | 343 | 187 | 209 | 59 |
| Net profit | 919 | 1 240 | 463 | 740 | −289 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 696 | 3 104 | 3 104 | 3 805 | 2 710 |
| Equity | 1 519 | 2 759 | 2 794 | 3 534 | 2 545 |
| Long-term debt | 0 | 3 | 9 | 22 | 7 |
| Short-term debt | 178 | 343 | 301 | 249 | 158 |
| Total debt | 178 | 345 | 310 | 271 | 165 |
EBITDA margin
-11.0%
This company
15.8%
Market median
-170% vs market
20202024
Equity ratio
93.9%
This company
38.2%
Market median
+146% vs market
20202024
Return on equity
-11.4%
This company
18.4%
Market median
-162% vs market
20202024
Net profit margin
-19.7%
This company
8.1%
Market median
-343% vs market
20202024
Asset turnover
0.54×
This company
1.12×
Market median
-52% vs market
20202024
Debt / equity
0.06×
This company
0.62×
Market median
+90% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LJ Deputy Member | Deputy Member | 2008 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2008 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NORMEDISIN AS 
SAMISK TEKSTIL ASBoard members of NORMEDISIN AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lasse Johnsen Kvernmo | Deputy Member | 0 companies |
| Knut Johnsen | Chairman | 0 companies |